title: Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer.
abstract: Testicular germ cell tumours are classified into two major histological subgroups, seminomas and nonseminomas. All tumours display several recurrent chromosomal aberrations, but few target genes have been identified. Previous studies have shown that genome-wide hypermethylation of CpG islands is significantly more prevalent in nonseminomas than in seminomas. We have studied two potential target genes in testicular cancer. A series of 70 tumours were analysed for methylation of CpG sites in the O(6)-methylguanine-DNA methyltransferase (MGMT) gene promoter, and in exon 1alpha of the cyclin-dependent kinase inhibitor 2A gene (CDKN2A). In addition, eight microsatellite markers within and flanking these genes at chromosome arms 10q and 9p, respectively, were analysed for allelic imbalances. Allele alterations were frequently seen at 9p loci (47 out of 70, 67%), but none of the tumours (none out of 55) showed methylation of CDKN2A. On the other hand, a high frequency of MGMT promoter methylation (32 out of 69, 46%) was found, as well as allelic imbalances at 10q markers (50 out of 70, 71%). A significantly higher methylation frequency was found in nonseminomas (24 out of 35, 69%) compared to seminomas (eight out of 33, 24%) (P=0.0003, Fisher's exact test). Immunohistochemical analysis of the MGMT protein in a subgroup (n=20) of the testicular tumours supported the hypothesis of gene silencing being the functional consequence of the promoter methylation. In summary, our data suggest that inactivation of MGMT contributes to development of nonseminomatous testicular cancer.
authors.affiliation: Department of Tumour Biology, Institute for Cancer Research, The Norwegian Radium Hospital, 0310 Oslo, Norway.
authors.forename: B
authors.initials: B
authors.lastname: Smith-Sørensen
authors.forename: G E
authors.initials: GE
authors.lastname: Lind
authors.forename: R I
authors.initials: RI
authors.lastname: Skotheim
authors.forename: S D
authors.initials: SD
authors.lastname: Fosså
authors.forename: Ø
authors.initials: Ø
authors.lastname: Fodstad
authors.forename: A-E
authors.initials: AE
authors.lastname: Stenwig
authors.forename: K S
authors.initials: KS
authors.lastname: Jakobsen
authors.forename: R A
authors.initials: RA
authors.lastname: Lothe
mesh_terms: D000483:Alleles; D042846:CDC2-CDC28 Kinases; D018899:CpG Islands; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases / Q000235:genetics; D019175:DNA Methylation; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000235:genetics* / Q000378:metabolism; D011401:Promoter Regions, Genetic; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D013736:Testicular Neoplasms / Q000235:genetics*
chemical_list: D019853:O(6)-Methylguanine-DNA Methyltransferase; D017346:Protein Serine-Threonine Kinases; D042846:CDC2-CDC28 Kinases; C495894:CDK2 protein, human; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases